CULLINAN THERAPEUTICS INC (CGEM) Stock Price & Overview
NASDAQ:CGEM • US2300311063
Current stock price
The current stock price of CGEM is 14.35 USD. Today CGEM is up by 0.7%. In the past month the price increased by 2.28%. In the past year, price increased by 81.88%.
CGEM Key Statistics
- Market Cap
- 868.606M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.35
- Dividend Yield
- N/A
CGEM Stock Performance
CGEM Stock Chart
CGEM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CGEM. When comparing the yearly performance of all stocks, CGEM is one of the better performing stocks in the market, outperforming 90.88% of all stocks.
CGEM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CGEM. CGEM has a great financial health rating, but its profitability evaluates not so good.
CGEM Earnings
CGEM Forecast & Estimates
19 analysts have analysed CGEM and the average price target is 34.42 USD. This implies a price increase of 139.9% is expected in the next year compared to the current price of 14.35.
CGEM Groups
Sector & Classification
CGEM Financial Highlights
Over the last trailing twelve months CGEM reported a non-GAAP Earnings per Share(EPS) of -3.35. The EPS decreased by -10.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.04% | ||
| ROE | -53.8% | ||
| Debt/Equity | 0 |
CGEM Ownership
CGEM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.18 | 371.899B | ||
| AMGN | AMGEN INC | 15.37 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.1 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.62 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CGEM
Company Profile
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 109 full-time employees. The company went IPO on 2021-01-08. The company has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
Company Info
IPO: 2021-01-08
CULLINAN THERAPEUTICS INC
One Main Street, Suite 1350
Cambridge MASSACHUSETTS 02142 US
CEO: Owen Hughes
Employees: 109
Phone: 16174104650
CULLINAN THERAPEUTICS INC / CGEM FAQ
What does CGEM do?
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 109 full-time employees. The company went IPO on 2021-01-08. The company has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.
What is the current price of CGEM stock?
The current stock price of CGEM is 14.35 USD. The price increased by 0.7% in the last trading session.
Does CGEM stock pay dividends?
CGEM does not pay a dividend.
What is the ChartMill technical and fundamental rating of CGEM stock?
CGEM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for CGEM stock?
19 analysts have analysed CGEM and the average price target is 34.42 USD. This implies a price increase of 139.9% is expected in the next year compared to the current price of 14.35.
Who owns CULLINAN THERAPEUTICS INC?
You can find the ownership structure of CULLINAN THERAPEUTICS INC (CGEM) on the Ownership tab.
What is the Short Interest ratio of CULLINAN THERAPEUTICS INC (CGEM) stock?
The outstanding short interest for CULLINAN THERAPEUTICS INC (CGEM) is 14.11% of its float.